LPCN - Lipocine Inc.
IEX Last Trade
4.72
-0.190 -4.025%
Share volume: 33
Last Updated: Thu 26 Dec 2024 08:19:49 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$4.91
-0.19
-3.87%
Fundamental analysis
24%
Profitability
25%
Dept financing
15%
Liquidity
50%
Performance
19%
Performance
5 Days
2.04%
1 Month
10.82%
3 Months
5.56%
6 Months
-37.60%
1 Year
67.17%
2 Year
-27.97%
Key data
Stock price
$4.72
DAY RANGE
$4.91 - $4.91
52 WEEK RANGE
$2.90 - $11.79
52 WEEK CHANGE
$72.47
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Mahesh V. Patel
Region: US
Website: lipocine.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lipocine.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Lipocine focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy.
Recent news